|
The next NIH Small Business
Innovation Research (SBIR) and Small Business Technology Transfer (STTR)
application deadline is Tuesday September
6, 2016, 5 pm local time. The National Heart, Lung, and Blood Institute
(NHLBI) welcomes all investigator-initiated projects within our
mission through the Omnibus funding opportunities:
-
SBIR (PA-16-302) and STTR (PA-16-303) Omnibus Solicitations
for Phase I, Phase II, and Fast-Track applications
-
SBIR
Direct-to-Phase II
Pilot (PAR-14-088) for Direct to Phase II applications.
Note: the standard SBIR/STTR
due date of September 5 falls on a Federal holiday, so the deadline for
SBIR/STTR is September 6.
Submit via ASSIST
ASSIST
helps streamline the electronic submission process. Try submitting with ASSIST
before the September 6 deadline! Questions? http://bit.ly/ASSIST_Info
Use SBIR/STTR
Application Instructions, Forms Version D
Make sure you’re using the new “Forms Version D” SF424
SBIR/STTR Application Guide and Supplemental Grant Application
Instructions: http://bit.ly/SF424-SB-formsD
Find additional useful resources from NIH SBIR: http://bit.ly/SBIR_Resources
Contact
the eRA Service Desk
(http://bit.ly/eRA_ServiceDesk) for electronic
submission questions.
Toll-free: 1-866-504-9552
Phone: 301-402-7469
Hours: Mon-Fri, 7 a.m. to 8 p.m. Eastern Time (closed on federal
holidays)
Additional Funding
Opportunities Due Fall 2016
-
September
6 - New Technologies for Viral Hepatitis (SBIR PA-15-077 STTR PA-15-076)
-
September 6 - Commercialization Readiness Pilot
(CRP) Program: Technical Assistance for Phase II Awardees - (SB1 PAR-16-026, Notice about NHLBI participation NOT-HL-15-283)
-
October 14 – Bioreactors for Reparative Medicine (SBIR RFA-HL-15-008 STTR RFA-HL-15-004 D2P2 RFA-HL-15-017)
-
October 15 - Onsite Tools and Technologies for Heart, Lung, and Blood Clinical Research Point-of-Care (STTR RFA-HL-14-017)
-
November 9 – Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (SBIR RFA-HL-15-027)
View all NHLBI targeted funding opportunities on our website (http://bit.ly/NHLBI-SBIR-FOA).
Register for the August 24, 2 pm EDT
pre-proposal webinar: HERE
Proposals
due October 21, 5 pm EDT
The annual NIH and
CDC SBIR Contract Solicitation (PHS2017-1) has been released (http://bit.ly/PHS2017-1). New electronic submission process
for contract proposals through the Contract Proposal Submission (eCPS) website:
https://ecps.nih.gov/sbirsttr. See NOT-OD-16-123 for all NIH and CDC
topics, contracting officer contact information, and other details.
-
098 Testing and Validation of
Technologies for Inclusion in the CART Demonstration Project for
Collaborative Aging Research
-
099 Inhalational 5A
Apolipoprotein A-I Mimetic Peptide for the Treatment of Asthma (SBIR-TT)
-
100 MRI Myocardial Needle
Chemoablation Catheter
-
101 Membranous Ventricular
Septal Defect (pmVSD) Transcatheter Occluder System
-
102 Transcatheter Occluder
Device for Paravalvular Leaks
Please direct all inquiries on the contract process or topics to:
Mr. John Taylor, taylorjc@nhlbi.nih.gov
All questions must be submitted by September 1, 2016.
The NHLBI accepts
investigator-initiated grant applications relevant to the NHLBI mission through the Omnibus Grant Solicitations. NHLBI has
identified specific Topics of Special Interest though we also encourage mission-aligned applications for
innovative technologies outside these targeted areas. Applications for
TOSI are submitted in response to the Omnibus Grant Solicitations (SBIR PA-16-302, STTR PA-16-303, and Direct to Phase II
SBIR PAR-14-088).
TOSI are not the same as the list of topics
approved for awards over statutory budget limitations; for these waiver topics,
please see Appendix
A of the Program Descriptions and Research Topics document.
-
HLS17-01 Animal and
Cellular Models: for rare non-malignant and pre-malignant (MDS &
MPD) hematologic disorders; for complications associated with thrombosis;
for transfusion of blood products or cell-based therapies
-
HLS17-02 Research
tools: Imaging, reagents, assays including microassays,
microfluidics, bioinformatics and nanotechnology for investigations of
blood diseases, transfusion and cellular therapies
-
HLS17-03 Diagnostics:
devices, biomarkers, imaging, and assays for non-malignant blood disorders
-
HLS17-04 Therapeutics:
drugs, blood product and cellular therapies, and gene therapy for
non-malignant blood disorders
-
HLS17-05 E-medicine Apps
for patients and medical professionals to improve the management of
and reduce the impact of non-malignant blood diseases
-
HLS17-06 Development of molecular
imaging reagents/techniques and nanotechnology-based drug delivery systems
that detect and allow for specific targeting of lung diseases
-
HLS17-07 Development of reagents
and methods to identify and isolate stem/progenitor cells, and direct
differentiation to specific functional organ units.
-
HLS17-08 Development and validation of techniques(or algorithms) to study the microbiome in situ
-
HLS17-09 Characterization and in vivo or in vitro applications
of miRNA panels that target
lung-resident mesenchymal or fibroblast cells and directly or
indirectly promote lung repair or regeneration.
-
HLS17-10 Development of high throughput methods to apply microfluidics technology in discovery of
molecular profiles
(DNAs, RNAs, proteins, or metabolites) in a large number of sputum or
exhaled breath condensate samples collected from lung disease
patients.
-
HLS17-11 High-definition, conformal, biocompatible mesh technologies made from nanoscale materials
are revolutionizing electronic-tissue interfaces.
-
HLS17-12 Develop new and improved methods to assess, monitor, or predict cardiovascular
toxicity of therapeutic agents.
-
HLS17-13 For citizens returning to an urban environment after
release from prison or jail, develop and validate mobile app solutions they can use to improve their health outcomes
related to cardiovascular diseases including but not limited to
hypertension.
-
HLS17-14 New animal models for the study of chronic venous insufficiency (CVI) and
post-thrombotic syndrome, and innovative approaches for their
prevention and treatment.
-
HLS17-15 Development of mechanical
circulatory support devices for individuals with congenital heart
disease and single ventricle physiology after Fontan surgical palliation.
-
HLS17-16 Novel non-invasive strategies that detect early
subclinical changes in cardiac structure, function, and /or tissue are
needed to improve detection and
monitoring of chemotherapy-induced cardiac injury in order to improve
cardioprotection and effectiveness of cancer therapeutics.
-
HLS17-17 Develop innovative technology and/or service delivery
models or designs to increase the
adoption, uptake, and sustainability of evidence-based guideline
recommendations for the management of heart, lung, blood, and sleep
disorders. These should include multi-level (health systems, provider, and
patient) facets and benefit ethnic/racial minority groups, rural
populations, and low socioeconomic status groups.
9/13 - RESI 2016
– Boston, MA
9/19 - 9/20 - Arizona
Bioscience Week (AZBio) – Phoenix, AZ
9/29 - 9/30 - 14th
Annual Dartmouth Device Development Symposium – Woodstock, VT
10/17 - 10/19 - AdvaMed 2016 –
Minneapolis, MN
10/18 - 10/19 - BIO Investor Forum –
San Francisco, CA
11/1 - NHLBI
Innovation Conference – New York City, NY
11/1 - 11/3 - SSTi
2016 Annual Conference – Columbus, OH
11/2 - 11/3 - Life
Sciences Summit – New York City, NY
11/13 - 11/15 - Partnering
for Cures – New York City, NY
11/15 - 11/17 - 18th Annual HHS SBIR/STTR Conference - Orlando, FL
|
